流感嗜血菌A-F型凝集抗血清Haemophilus

廣州健侖生物科技有限公司

本試劑盒主要用于對(duì)病菌細(xì)菌進(jìn)行檢測(cè)，利用快速玻片凝集檢測(cè)技術(shù)，對(duì)大腸桿菌培養(yǎng)物進(jìn)行血清學(xué)鑒定。本試劑盒僅供科研使用。

保存要求：除了有特殊說明，免疫檢測(cè)產(chǎn)品應(yīng)保存在2-8°C

產(chǎn)品規(guī)格：2ml/瓶

保質(zhì)期：2年

流感嗜血菌A-F型凝集抗血清Haemophilus

【流感嗜血桿菌相關(guān)知識(shí)】

流感嗜血桿菌分類為兩類，即莢膜菌株及沒有莢膜的菌株。雖然已知莢膜類的乙型流感嗜血桿菌（或是b型流感嗜血桿菌，簡稱HiB）是毒性的主因之一，但感染流感嗜血桿菌的病因卻仍未*清楚。它們的莢膜能幫助它們抵抗在沒有免疫的寄主體內(nèi)的吞噬作用及不觸發(fā)補(bǔ)體介導(dǎo)的裂解。沒有莢膜的菌株則較少侵略性，但它們能誘發(fā)炎癥而產(chǎn)生其他病癥，如會(huì)厭炎。

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

（ MOB：楊永漢） 

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103

免疫檢 測(cè)T細(xì)胞分化抗原測(cè)定【中文名稱】T細(xì)胞分化抗原測(cè)定【概述】T 細(xì)胞膜表面有100多種特異性抗原，現(xiàn)已制備了多種單克隆抗體， WHO（1986）統(tǒng)稱為白細(xì)胞分化抗原（cluster  differentiation，CD）。例如CD3代表總T細(xì)胞，CD4代表T輔助 細(xì)胞（TH），CD8代表T細(xì)胞毒性細(xì)胞（TC）等。應(yīng)用這些細(xì)胞的 單克隆抗體與T細(xì)胞表面抗原結(jié)合后，再與熒光標(biāo)記二抗（兔或羊 抗鼠IgG）反應(yīng)，在熒光顯微鏡下或流式細(xì)胞儀中計(jì)數(shù)CD的百分率 。【參考值】免疫熒光法（IFA）：CD3為63.1%±10.8%；CD4 （TH）為42.8%±9.5%；CD8（TS）為19.6%±5.9%；CD4/CD8 （TH/TS）為（2.2±0.7）/1。流式細(xì)胞術(shù)：CD3為61%～85%； CD4為28%～58%；CD8為19%～48%；CD4/CD8為0.9～2.0/1?！九R 床意義】①CD3降低：見于自身免疫性疾病，如SLE、類風(fēng)濕關(guān)節(jié) 炎等。②CD4降低：見于惡性腫瘤、遺傳性免疫缺陷癥、艾滋病、 應(yīng)用免疫抑制劑者。③CD8減低：見于自身免疫性疾病或反應(yīng)性疾 病。④CD4/CD8比值增高：見于惡性腫瘤、自身免疫性疾病、病毒 性感染、反應(yīng)等；CD4/CD8比值減低：見于艾滋?。ǔ?lt;0.5）。
Immunoassay T cell differentiation antigen determination [Chinese name] T cell differentiation antigen measurement [Overview] T cell membrane surface has more than 100 kinds of specific antigens, has produced a variety of monoclonal antibodies, WHO (1986) collectively referred to as leukocyte differentiation antigen ( Cluster differentiation, CD). For example, CD3 represents total T cells, CD4 represents T helper cells (TH), CD8 represents T cell cytotoxic cells (TC) and the like. After the monoclonal antibodies using these cells were combined with the T cell surface antigen, they reacted with a fluorescently labeled secondary antibody (rabbit or goat anti-mouse IgG) and the percentage of CD was counted under a fluorescence microscope or in a flow cytometer. [Reference value] Immunofluorescence assay (IFA): CD3 was 63.1% ± 10.8%; CD4 (TH) was 42.8% ± 9.5%; CD8 (TS) was 19.6% ± 5.9%; CD4/CD8 (TH/TS) was (2.2 ± 0.7)/1. Flow cytometry: CD3 was 61% to 85%; CD4 was 28% to 58%; CD8 was 19% to 48%; CD4/CD8 was 0.9 to 2.0/1. [Clinical significance] 1CD3 reduction: seen in autoimmune diseases such as SLE, rheumatoid arthritis and so on. 2CD4 reduction: seen in malignant tumors, hereditary immunodeficiency, AIDS, and immunosuppressive agents. 3CD8 reduction: seen in autoimmune or reactive disease. 4CD4/CD8 ratio increased: seen in malignant tumors, autoimmune diseases, viral infections, reactions, etc.; CD4/CD8 ratio decreased: seen in AIDS (usually <0.5).